About

Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using big data and AI to accelerate treatments for rare diseases. He is the Co-Founder and Chief Executive of Healx, the AI-powered, patient-inspired tech company, accelerating the discovery and development of rare disease treatments at scale. In 2019, Healx raised $56 million in Series B funding and was listed in Tech Nation’s Future Fifty cohort. In 2020, the company won 5 prizes at the CogX Awards including Grand Jury Prize and Best AI Product and was listed in CB Insights Digital Health 150.

As CEO of Healx, Tim has been listed in The Sunday Times Maserati 100 list of entrepreneurs in 2019, was named as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020, and was selected as member of the Forbes Technology Council in 2022.

Prior to Healx Tim obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease. Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.

Bruce is the founder and former CEO of Cures Within Reach, a global non-profit dedicated to repurposing approved drugs, devices, and diagnostics to create new, affordable treatments for diseases without current therapies. He also envisioned and developed CureAccelerator®, the first online platform connecting clinicians, researchers, funders, and industry to drive redevelopment research.

Currently, Bruce serves as Chief Science Officer for both the Kabuki Syndrome Foundation and the Goldman Philanthropic Partnerships, and he is the CEO of Fortuity Pharma, a public benefit corporation focused on developing repurposed therapies for nano-rare diseases.

Bruce’s other leadership roles include serving as an Ashoka Social Entrepreneur Fellow, Chair of the Patient Advisory Board for the Institute for Translational Medicine, and board member of various organisations such as Every Cure, Mission: Cure, and the Rare Disease Research Hub. He is also on the editorial board of ASSAY and Drug Development Technologies.

Mark is an experienced business development leader. As the Global Head of Business Development and Licensing, he is responsible for leading Healx's strategic and business development initiatives.

Prior to joining Healx, Mark was the Global Head of Business Development at Acrotech Biopharma where he successfully closed multiple transactions to help build the company from the start. Previously, he has also worked in Business Development at Bayer and held various positions in the pharmaceutical industry.

Mark has a Doctor of Pharmacy degree, Masters in Business Administration and post-doctoral fellowship training from Rutgers University.

Nick is a seasoned technology leader with a proven track record of building and leading highly effective, cross-disciplinary teams. As Head of Operations, People and Tech at Healx, Nick ensures the seamless daily operations of the company while also overseeing People and Technology, driving excellence across these critical functions.

With a wealth of experience spanning multiple industries, Nick has developed software products for startups, enterprise organisations, and consultancy firms. Prior to joining Healx, Nick was instrumental in establishing Pivotal Labs in the UK, where he led the North EMEA business and managed consulting teams across Europe. Nick has guided companies in transforming their software development strategies by adopting lean agile, user-centric, and modern cloud methodologies.

Nick holds a Master’s degree in Computer Science with Artificial Intelligence from Imperial College London, further solidifying his expertise in technology leadership.

With over 25 years of experience in drug discovery, Richard has advanced multiple preclinical candidates and led projects in inflammatory, metabolic, CNS, and rare disease research. He began his career at Chiroscience, one of the UK's pioneering biotech companies, where he quickly rose through the ranks as the company evolved, eventually merging with Celltech and UCB.

Richard played a pivotal role in establishing UK-based NCE (New Chemical Entity) drug discovery capabilities for Takeda before joining C4X Discovery, where he utilized the company’s innovative 4D molecule visualizer NMR technology to design novel NCEs. Currently, at Healx, Richard oversees the pipeline and preclinical drug discovery activities, applying his passion for automation and novel technologies to increase the success rate of projects reaching the clinic.

Miguel has over 20 years of experience in genomics, health sciences, and biomedical research. He has been at the forefront of developing new methods for the functional annotation of genomes and metagenomes, with a focus on health and disease. Over the past decade, Miguel has applied his expertise to the creation of technological platforms aimed at revolutionizing early drug discovery.

Miguel played a pivotal role in the early development of the OpenTargets platform, a groundbreaking public-private partnership that leverages human genetics and genomics data for systematic drug target identification and prioritisation.

Since joining Healx in 2018, Miguel has spearheaded the development of critical components within the company's drug discovery pipeline. Currently, he is focused on establishing Healx’s tech strategy and roadmap, ensuring seamless alignment between the scientific and technological teams to drive innovation and advance drug discovery efforts.

Simone is deeply passionate about advancing treatments for Neurofibromatosis (NF), a cause close to his heart due to his personal connection with the condition and the NF community. As Head of Neurofibromatosis Therapy Development at Healx, he leads the company’s NF programme, driving innovation in this crucial area.

In addition to his role at Healx, Simone actively serves the NF community as a member of the Board of Directors for the Children’s Tumor Foundation, the leading not-for-profit organisation dedicated to ending NF through research.

Before joining Healx, Simone held senior HR roles in the financial and biotech sectors across Ireland and Switzerland. He holds a degree in Psychology and an Executive M.B.S. in Human Resource Strategies from DCU in Dublin.